Leptin Induces an Inflammatory Phenotype in Lean Wistar Rats by Allman, Monique et al.
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2009, Article ID 738620, 8 pages
doi:10.1155/2009/738620
Research Article
LeptinInducesan Inﬂammatory Phenotypein Lean Wistar Rats
MoniqueAllman, Mathew Wallace, LataushaGaskin,andChantal A. Rivera
Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center, 1501 Kings Hwy, Shreveport,
LA 71130, USA
Correspondence should be addressed to Chantal A. Rivera, crive1@lsuhsc.edu
Received 20 July 2009; Revised 29 September 2009; Accepted 15 October 2009
Recommended by Oreste Gualillo
Thepresentstudyaddressedthehypothesisthatleptinpromotesleukocytetraﬃckingintoadiposetissue.Accordingly,maleWistar
rats were treated with saline or recombinant rat leptin (1mg/kg) via the tail vein. Leukocyte traﬃcking in mesenteric venules was
quantiﬁed by intravital microscopy. Treatment with leptin resulted in a 3- and 5-fold increases in rolling and ﬁrm adhesion,
respectively. Compared to vehicle controls, leptin enhanced mRNA levels of IL-6 (8-fold) and MCP-1 (5-fold) in mesenteric
adipose tissue (MAT). Similar increases in these markers were observed in mesenteric venules and in liver. Finally, the direct eﬀect
of leptin was assessed in C3A hepatocytes treated with leptin for 24 hours (7.8ng/mL–125ng/mL). Consistent with observations
in vivo, production of ICAM-1,MCP-1, and IL-6 by hepatocytes was increased signiﬁcantly. These ﬁndings support the hypothesis
that leptin directly initiates inﬂammation in the local environment of mesenteric adipose tissue as well as systemically.
Copyright © 2009 Monique Allman et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Obesity is reaching epidemic proportions in the United
States as well as many other countries. The degree of
adiposity, visceral adiposity in particular, correlates with the
extent of obesity-associated comorbid conditions such as
hypertension, diabetes, and cardiovascular disease. More-
over, it is believed that abdominal adiposity plays a key role
in the chronic inﬂammatory state that predisposes to these
comorbidities [1–3]. For example, a positive correlation
exists between adiposity (i.e., BMI and % body fat), IL-6
p r o t e i nl e v e l si ns e r u m ,a sw e l la sm R N Al e v e l so ft u m o r
necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) in
abdominal adipose tissue [4, 5]. Consequently, recent exper-
imental and clinical research has focused on elucidating the
contributionofadiposetissuetothedevelopmentofsystemic
pathologies.
Growing adipose tissue depots are characterized by
enhanced macrophage content and the induction/activation
of several proinﬂammatory genes. Adipocyte conditioned
medium induces the expression of leukocyte-endothelial cell
adhesion molecules, and stimulates monocyte diapedesis
across monolayers of cultured endothelial cells [6]. How-
ever, speciﬁc factors responsible for vascular inﬂammation
observed during the growth of adipose cells have not been
fully elucidated. Leptin is a hormone produced in adipocytes
that regulates both food intake and energy expenditure.
Importantly, it appears that serum leptin may represent an
independent predictor of the severity of illnesses associated
with obesity. In fact, hyperleptinemia is an independent
predictor of nonalcoholic steatohepatitis (NASH) in obese
humans, and the severity of steatosis, hepatocyte balloon-
ing, as well as nonalcoholic fatty liver disease (NAFLD)
activity scores correlate with serum leptin levels [7]. Based
on ﬁndings linking leptin to systemic inﬂammation, it is
hypothesized that leptin can directly modulate the inﬂam-
matory response in the vasculature and liver. Accordingly,
we performed intravital microscopic analysis to examine
the direct eﬀects of bolus (1mg/kg) intravenous leptin
administration on leukocyte-endothelial cell interactions in
the rat mesenteric microvasculature. This dose was chosen in
an attempt to mimic hyperleptinemia as described by others
[8, 9]. The eﬀects of hyperleptinemia on the liver in vivo and
on cultured hepatocytes were also monitored. Our results
provide the ﬁrst real-time evidence that leptin promotes
leukocyte traﬃcking in the microvasculature and directly
stimulates a proinﬂammatory phenotype in hepatocyte
cultures.2 Mediators of Inﬂammation
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Figure 1: Leukocyte traﬃcking in the mesenteric microvasculature. Wistar rats (200–250g) were subjected to intravital microscopic analysis of
leukocytetraﬃckinginmesentericpostcapillaryvenules.(a)Occasionalrollingandadherentleukocytes wereobservedinmesentericvenules
in saline controls. (b) Mesenteric venules 24 hours after leptin administration (1mg/kg i.v.) displayed a marked enhancement in leukocyte
traﬃcking as denoted by arrows. (c) Summary of control and leptin-stimulated leukocyte traﬃcking. Data are mean ± SEM analyzed by
one-way ANOVA; ∗P<.05 compared to control.
2.MaterialsandMethod
2.1.Materials. HumanC3Ahepatocytesandculturereagents
were purchased from ATCC, (Manassas, VA). Leptin was
obtained from Sigma-Aldrich (St. Louis, MO). An RNeasy
Mini Kit, for RNA extraction, was purchased from Qiagen
(Valencia, CA). DuoSet ELISA kits for Human ICAM-1, IL-
6, and MCP-1 as well as ELISA kits for rat Adiponectin were
purchased from R&D Systems (Minneapolis, MN). Gene
expression Assays for real-time PCR were obtained from
Applied Biosystems (Foster City, CA).
2.2. Animal Treatment and Intravital Microscopy. Male Wis-
tar rats were administered saline (controls; n = 6) or recom-
binant rat leptin (1mg/kg; n = 6) via the tail vein. This dose
was based on previously reported doses for rodent studies [8,
9]. After 4 hours or 24 hours, intravital microscopy was used
to monitor and quantify leukocyte traﬃcking as described
previously [10]. Brieﬂy, while under ketamine hydrochloride
(150mg/kg i.m.) and xylazine (7.5mg/kg i.m.) anesthesia, a
laparatomywasperformedandasmallportionofthemesen-
terywasexteriorized.AnOlympusIX71invertedmicroscope
equipped with a Sony DSP 3CCD color video camera was
used to record each intravital experiment for oﬄine analysis.
Vessels chosen for analysis were approximately 20–50μmi n
diameter. At least 3 non-overlapping regions were analyzed
for each rat. Rolling leukocytes were deﬁned as cells moving
at a velocity signiﬁcantly slower than center line velocity.
Adherent leukocytes were determined as cells that were
completely stationary for at least 30 seconds.
2.3. Hepatic Histology. At the end of the intravital analysis,
samples of liver were ﬂash-frozen in liquid nitrogen and
stored at −80◦C for RNA extraction. Additional samples
were preserved in zinc ﬁxative, processed with paraﬃn, and
4μm sections were stained with hematoxylin and eosin.
Hepatic injury and inﬂammation were assessed by one of the
authors blinded to the study design.
2.4. Cell Culture. Human C3A hepatocytes were grown to
conﬂuence in Eagle’s Minimum Essential Media (EMEM)
supplemented with 10% Fetal Bovine Serum (FBS). When
cultures reached conﬂuence, C3A cells were incubated
overnight in EMEM medium without FBS for 24 hours
prior to treatment with recombinant human leptin (7.8–
125ng/mL). After an additional 24 hours period in the
presence of leptin, the culture medium was collected andMediators of Inﬂammation 3
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Figure 2: The relative mRNA expression of MCP-1 and P-selectin.
Expressions of (a) MCP-1 and (b) P-selectin were assessed using
pre-developed assays for real-time PCR according to the manu-
facturer’s instructions (Applied Biosystems). Values were calculated
using a comparative Ct method and presented as mean ± SEM of at
least 4 observations/group. Statistical analysis was performed using
student’s t-test. ∗P<.05 saline controls.
the cells were harvested. The cell pellet was stored at −80◦C
u n t i lu s e df o rR N Ae x t r a c t i o n .
2.5. Measurement of Inﬂammation Markers. At the time of
sacriﬁce, samples of whole blood were collected from the
vena cava of saline controls and leptin-treated rats. Serum
levels of the anti-inﬂammatory adipokine adiponectin were
determined by ELISA. Soluble ICAM-1, IL-6, and MCP-
1 were measured in samples of culture medium collected
24 hours after leptin exposure using Duoset ELISA kits
according to the manufacturer’s instructions.
2.6. RNA Isolation and Reverse Transcription. Total RNA
was extracted from frozen samples of mesenteric adipose
tissue, mesenteric connective tissue containing microvessels,
and liver using the RNeasy Mini kit from Qiagen. The
integrity and concentration of each total RNA sample were
determined by spectrophotometry. A 500ng aliquot of total
RNA was reverse-transcribed to cDNA in 25μLo fr e a c t i o n
mixture containing 25mMMgCl2, 10mMdNTPmix, 50μM
Random hexamers, 20U/uL RNase inhibitor, and 50U/uL
multiscribe reverse transcriptase. Reaction mixtures were
incubated in a Mastercycler-personal (Eppendorf, Westbury,
N Y )f o r1 0m i n u t e sa tr o o mt e m p e r a t u r ef o l l o w e db y6 0
minutes at 42◦C and 5 minutes at 95◦C.
2.7. Quantitative Real-Time Polymerase Chain Reaction.
Relative mRNA expression of ICAM-1, MCP-1, IL-6, and P-
selectin was determined using predeveloped assays for real-
time PCR (Applied Biosystems, Foster City, CA). Analysis of
each target mRNA was performed in duplicate in separate
wells and normalized to ampliﬁcation of 18S ribosomal
RNA subunit. To conﬁrm the absence of genomic DNA
contamination, samples without the reverse transcription
were also analyzed. The reactions were performed using
an ABI Prism 7700 Sequence Detection System with the
following cycle parameters: 50◦Cf o r2m i n u t e s ,9 5 ◦Cf o r
10 minutes followed by 40 cycles of 95◦C for 15 seconds
and 60◦C for 1 minute. Raw data were analyzed using the
ABI Prism Sequence Detection 1.9.1 software. The relative
amount of mRNA was calculated using the comparative
threshold cycle (Ct) method as described previously [11].
2.8. Statistical Analysis. Data are presented as mean ± SEM
of 4–6 observations per treatment group. Statistical analysis
was performed using student’s t-test or one-way ANOVA
with Tukey’s multiple comparisons test where appropriate
as indicated in the ﬁgure legends; P<.05 was selected as the
level of signiﬁcance.
3. Results
3.1. The Eﬀects of Leptin on Leukocyte Traﬃcking In Vivo.
The in vivo response to leptin was investigated using video
microscopy of leukocyte rolling and ﬁrm adhesion in the
mesenteric microvasculature 24 hours after leptin treat-
ment. Representative photomicrographs of the vasculature
are presented in Figures 1(a) and 1(b). As summarized
in Figure 1(c), there was a signiﬁcant 3-fold increase in
rolling as well as adherent leukocytes along the vascular
endothelium compared to saline-treated control rats 24
hours after leptin treatment.
To further index the vascular response to leptin, mesen-
teric tissue containing microvessels was isolated separately
from gut and adipose tissue for analysis of mRNA levels of
the inﬂammatory mediators MCP-1 and P-selectin. Expres-
sion of both markers was enhanced signiﬁcantly by more
than 25-fold and 2-fold, respectively, in rats administered
leptin (Figure 2).
3.2. Eﬀe c to fL e p t i no nA d i p o s eT i s s u e . To determine whether
leptin plays a role in adipose tissue inﬂammation, expression
of MCP-1 and IL-6 was assessed in samples of mesen-
teric adipose tissue collected 24 hours after intravenous
leptin treatment. Compared to control rats administered
saline, mRNA levels of MCP-1 were increased nearly 6-
fold (Figure 3(a)). Expression of IL-6 was also signiﬁcantly4 Mediators of Inﬂammation
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Figure 3: Eﬀects of leptin on adipose tissue, serum adiponectin, and liver. Samples of mesenteric adipose tissue, serum and liver were collected
from leptin-treated rats (1mg/kg via the tail vein) and saline controls, and the following parameters were measured: Expressions of (a)
MCP-1 and (b) IL-6 in samples of mesenteric adipose tissue were assessed using predeveloped assays for real-time PCR according to the
manufacturer’s instructions (Applied Biosystems). Values were calculated using a comparative Ct m e t h o d .( c )S e r u ml e v e l so fa d i p o n e c t i n
were measured by ELISA. (d) Hepatic mRNA expression of ICAM-1 was measured by real-time PCR. Data are presented as mean ± SEM of
at least 4 observations/group. Statistics were performed using Student’s t-test ∗P<.05 compared to saline controls.
enhanced by approximately 9-fold above control levels
(Figure 3(b)). Serum samples were analyzed to determine
the presence of adiponectin. As shown in Figure 3(c), the
amount of adiponectin protein in serum of control rats
was approximately 13.9 ± 1.6mg/mL, but was decreased
signiﬁcantly to 8.6 ± 0.3mg/mL by leptin. Thus, leptin
stimulates expression of proinﬂammatory mediators while
inhibiting the production of the potentially beneﬁcial hor-
mone adiponectin.
3.3. Eﬀects of Leptin on the Liver. Since obesity and hyper-
leptinemiaarealsoassociatedwiththehepaticdiseaseknown
as nonalcoholic steatohepatitis, we next determined if leptin
administration promotes hepatic inﬂammation. Histological
samples of liver collected at 4 hours or 24 hours after leptin
injectiondidnotdisplayanovertaccumulationofleukocytes
or injury (data not shown). On the other hand, PCR analysis
of ICAM-1 expression revealed a 2-fold increase in mRNA
levels at the 24 hours time point (Figure 3(d)), suggesting
that leptin promotes hepatic inﬂammation and the potential
for leukocyte accumulation.
3.4. Eﬀects of Leptin on Cultured Hepatocytes. The C3A
human hepatocyte cell line was used to determine if
leptin exposure could directly stimulate a proinﬂammatory
phenotype. After up to 24 hours in culture, protein and
mRNA expression of ICAM-1 was monitored using ELISA
and real-time PCR, respectively. Protein levels of sICAM
released by C3A cells increased in a dose-dependent manner
(Figure 4(a)). Leptin maximally increased sICAM release byMediators of Inﬂammation 5
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Figure 4: Eﬀect of leptin on hepatocytes. Human C3A hepatocytes
were cultured in the presence of leptin (0–125ng/mL) for 24 hours.
(a) The release of soluble ICAM-1 into the culture medium and
(b) ICAM-1 mRNA levels was quantiﬁed by ELISA and real-time
PCR,respectively. Statistics were performed using one-way ANOVA
∗P<.05 compared to vehicle control cultures.
approximately 1.5-fold at a dose of 62.5ng/mL leptin. The
mRNA levels of ICAM-1 were also increased signiﬁcantly
compared to vehicle control cultures (Figure 4(b)). Because
the peak eﬀect of leptin was observed at a concentration
of 62ng/mL, the remaining experiments were performed
using only this dose. Finally, protein levels of MCP-1
and IL-6 were quantiﬁed using ELISA to further index
the inﬂammatory state in hepatocytes. In the samples of
culture medium collected from untreated cells, the amount
of MCP-1 produced was approximately 6.4 ± 0.3ng/mL
(Figure 5(a)). Leptin treatment increased MCP-1 concentra-
tions to 9.4 ± 1.2ng/mL. In addition, the production of IL-
6 was signiﬁcantly enhanced by approximately 5-fold (4.4
± 0.5pg/mL) compared to vehicle control cultures (09. ±
0.3pg/mL; Figure 5(b)).
4. Discussion
Leptin is 16kDa protein primarily known for regulation of
caloric load via appetite suppression and energy expenditure
under normal physiological conditions. Mutations in the
leptin (Ob) or leptin receptor (Obr) genes inhibit the
appropriate production of or response to leptin, respectively.
Although rare in humans, these mutations render aﬀected
individuals obese. On the other hand, obesity as a result
of poor life style choices (e.g., hyperphagia, sedentary
behavior) is commonly associated with hyperleptinemia.
Several studies have shown that serum leptin levels correlate
with generalized obesity indexed by BMI and even more
speciﬁcallywithabdominaladiposity. Considine etal.(1996)
wereamongtheﬁrsttoreportapositiverelationshipbetween
leptin and adiposity [12]. They reported signiﬁcantly higher
serum leptin levels of 31.3 ± 24.1ng/mL in obese subjects
compared to lean controls (7.5 ± 9.3ng/mL). Protein levels
as well as leptin gene expression in adipocytes strongly
correlated with % of body fat, and hyperleptinemia was
improved withweightloss. Receptorsforleptin are expressed
throughout the body and leptin binding to these receptors
has been shown to stimulate adaptive as well as innate
immune response as reviewed elsewhere [9, 13, 14]. For
example, leptin has been shown to participate in the
pathogenesis of autoimmune encephalomyelitis causing a
profound down-regulation of the content of regulatory T
lymphocytes in the CNS ﬂuid [15, 16]. With respect to
innate immunity, leptin promotes monocyte/macrophage
activation states, a process that likely triggers neutrophil
chemotaxis [14, 17]. Moreover, this adipokine elicits the
activation of NFkB [18], a transcription factor that initiates
the synthesis of cell adhesion glycoprotein molecules (e.g.,
ICAM-1) and chemokines (e.g., MCP-1). In the setting of
diet-induced obesity, serum leptin levels correlate directly
with the presence of comorbidities such as cardiovascular
disease and liver disease. These ﬁndings have warranted
investigations into the possible pathogenic roles of leptin in
the genesis of comorbidities associated with obesity. Indeed,
the low-grade chronic inﬂammatory state that accompanies
obesity is thought to be a mitigating factor in the devel-
opment of cardiovascular abnormalities, liver disease, and
various other pathological conditions.
In terms of cardiovascular disease, plasma leptin levels
are reported to be an independent predictor of early
atherosclerotic events such as intima-media thickness [19,
20]. Previous studies in rodent models provide insight
into the inﬂuences of leptin on vascular disease; however,
results are equivocal and underlying mechanisms of vascular
reactivity remain to be elucidated as reviewed elsewhere
[21]. For example, Valeric et al. (2009) found that leptin
deﬁcientob/obmiceweremoresusceptibletostrokeinduced
by permanent cerebral artery occlusion [18]. In contrast,
Terao et al. reported exacerbated vascular injury that was
associated with enhanced leukocyte and platelet traﬃcking
in microvessels [22]. The acute (30 minutes) occlusive event
used in the latter study is likely more relevant to clinical
stroke. Moreover, leptin reconstitution in ob/ob mice further
augmented infarct volume, providing evidence that leptin6 Mediators of Inﬂammation
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Figure 5: Eﬀect of leptin on hepatocyte cytokine and chemokine release. Protein levels of IL-6 and MCP-1 produced by hepatocytes cultured
in the presence of 62.5ng/mL leptin for 24 hours were quantiﬁed using a high-sensitivity Quantikine ELISA kit (R&D systems, Inc). Data
are presented as mean ± SEM of at least 4 observations/group. Statistical analysis was performed using Student’s t-test ∗P<.05 compared to
vehicle control cultures.
has an adverse inﬂuence on the vasculature. In the present
study, we administered a bolus dose of leptin in an attempt
tomimicthehyperleptinemicstatethataccompaniesobesity.
Our ﬁndings provide strong support of a role for hyper-
leptinemia in the development of vascular and tissue injury,
however we focused speciﬁcally on inﬂammatory changes in
the microcirculation and not vascular reactivity. Our data
indicate that bolus intravenous leptin administration can
directly stimulate leukocyte and platelet interactions with
the endothelial lining of the mesenteric microvasculature,
most likely via alterations in proinﬂammatory cytokines and
chemokines. To our knowledge, this is the ﬁrst real-time
in vivo demonstration of the direct inﬂammatory eﬀects of
hyperleptinemia in lean rats in the absence of any underlying
pathological conditions.
Nonalcoholic steatohepatitis is a cryptogenic form of
liver disease that is often observed in obese patients without
identiﬁable causes such as alcohol abuse, drug toxicity,
or viral infection. As the name suggests, NASH is histo-
logically indistinguishable from alcoholic hepatitis and is
characterized by fat accumulation in hepatocytes, mixed
cell type inﬂammation, focal necrosis, and ﬁbrosis. This
disease has been observed worldwide and the prevalence
of NASH is estimated to be as high as 40–100% in obese
adults as reviewed elsewhere [23]. Adiposity is clearly one
of the most studied risk factors for NASH [24, 25]. It
has been proposed that abdominal adiposity is particularly
related to disease state [1–3]. With respect to on advanced
disease, a signiﬁcant positive correlation has been identiﬁed
between advanced ﬁbrosis stage and indices of adiposity
(e.g., BMI, blood cholesterol and LDL levels) [24–26]. The
precise mechanistic basis of NASH is not known; however
previous ﬁndings suggest that leptin may be an important
link between adiposity and liver injury in obese people.
Although it is primarily secreted by adipocytes, recent
reports demonstrated that leptin was also expressed by
activated stellate cells [9]. Interestingly, leptin enhanced the
expression of cytokines related to the induction of ﬁbrosis
in the liver (e.g., transforming growth factor-β,T G F - β)
and induced the overproduction of matrix proteins that are
components of ﬁbrosis scaring such as collagen αI-1 [9, 27–
29]. Moreover, in animal models of NASH, spontaneous
conversion from simple fat accumulation in hepatocytes to
injury and ﬁbrosis does not occur in leptin-deﬁcient ob/ob
mice [30]. Herein, we report that exposure of C3A human
hepatocytes to leptin induced a proinﬂammatory phenotype
characterized by enhanced expression of cytokines (IL-6),
chemokines (MCP-1), and the adhesion molecule ICAM-1.
Leptin administration in vivo signiﬁcantly enhanced hepatic
ICAM-1 expression. Taken together, the present ﬁndings
provide compelling evidence of a direct proinﬂammatory
eﬀect of hyperleptinemia on the liver. In addition, we found
that bolus leptin administration resulted in a decrease in
circulating serum adiponectin levels, an adipocyte-derived
hormone widely believed to have anti-inﬂammatory prop-
erties. In contrast to leptin, recent studies have identiﬁed
an inverse relationship between NASH severity and serum
adiponectin levels [31–33]. Studies in animal models of
NASH have conﬁrmed that hypoadiponectinemia augments
steatohepatitis, while transgenic mice that overexpress this
hormone were protected from pathology [34, 35]. Although
a correlation of the serum adiponectin/leptin ratio with
disease pathogenesis has been noted in humans with NASH
[31, 33], the exact mechanistic link between these two
adipokines remains to be elucidated.
5. Conclusion
Taken together with previous reports in rodent models
as well as humans, data presented herein demonstrate
the potential role for leptin in the inﬂammatory process
associated with obesity. Our working hypothesis is out-
lined schematically in Figure 6. Brieﬂy, in an obesigenic
environment, hyperleptinemia results from growing adiposeMediators of Inﬂammation 7
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Figure 6: Working hypothesis. Although leptin is constitutively
expressed and released by adipocytes, its expression is enhanced
during weight gain/fat deposition. We hypothesize that augmented
leptin release from growing adipocytes up-regulates adhesion
molecules on endothelial cells, which promote the subsequent
leukocyte invasion into adipose tissue. The production of inﬂam-
matory cytokines by invading leukocytes potentiates leptin syn-
thesis, which will ultimately have detrimental eﬀects on the local
microvasculaure. Since blood leaving the mesentery drains directly
into the portal circulation, leptin likely plays an important role in
the development of obesity-associated nonalcoholic steatohepatitis.
tissue depots. The overproduction of leptin stimulates the
synthesis of inﬂammatory mediators such as MCP-1 and
ICAM-1, which promote leukocyte traﬃcking in the local
microvasculature. As obesity, adipose tissue inﬂammation,
and the hyperleptinemic state become more exaggerated,
systemic inﬂammation ensues. Thus, although leptin is
thought to have some neuroprotective eﬀects [18, 36]a n d
has been the focus of several hundred pharmacological
intervention studies for weight loss as reviewed elsewhere
[37], therapeutic eﬃcacy of this adipokine will likely be
proven to be very limited in the setting of obesity due to
adverse eﬀects on immune function.
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